All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyDavid R. Nelson, Mordechai Rabinovitz, David Bernstein et al.|Hepatology|2015Cited by 689
NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosisJacqueline G. O’Leary, Jasmohan S. Bajaj, K. Rajender Reddy et al.|Hepatology|2018Cited by 270
The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosisJasmohan S. Bajaj, Jacqueline G. O’Leary, K. Rajender Reddy et al.|Hepatology|2015Cited by 237
Human bile contains MicroRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosisLing Li, Florin M. Selaru, David L. Masica et al.|Hepatology|2014Cited by 224
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Christopher L. Bowlus et al.|Journal of Hepatology|2020Cited by 10